Boehringer Ingelheim advances weight loss drug to Phase III trials
Depending on Phase III results, survodutide could soon enter the weight loss market, which is expected to reach $37.1bn by 2031.
Depending on Phase III results, survodutide could soon enter the weight loss market, which is expected to reach $37.1bn by 2031.
What's Your Reaction?
